| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 14.58% | Truist Securities | $10 → $11 | Maintains | Hold |
| 10/03/2023 | 56.25% | Needham | → $15 | Reiterates | Buy → Buy |
| 08/09/2023 | 35.42% | Credit Suisse | $15 → $13 | Maintains | Outperform |
| 08/09/2023 | 56.25% | Needham | $16 → $15 | Maintains | Buy |
| 05/11/2023 | 20.83% | Goldman Sachs | $13 → $11.6 | Maintains | Buy |
| 05/10/2023 | 66.67% | Needham | $17 → $16 | Maintains | Buy |
| 03/13/2023 | 62.5% | Goldman Sachs | $13.8 → $15.6 | Maintains | Buy |
| 03/10/2023 | 25% | RBC Capital | → $12 | Reiterates | → Sector Perform |
| 03/10/2023 | 4.17% | Truist Securities | $9 → $10 | Maintains | Hold |
| 03/10/2023 | 56.25% | Credit Suisse | $17 → $15 | Maintains | Outperform |
| 03/10/2023 | 43.75% | Goldman Sachs | $15.6 → $13.8 | Maintains | Buy |
| 03/10/2023 | 77.08% | Needham | → $17 | Reiterates | → Buy |
| 01/19/2023 | 25% | Stifel | → $12 | Downgrades | Buy → Hold |
| 11/21/2022 | 4.17% | Barclays | $9 → $10 | Maintains | Equal-Weight |
| 11/11/2022 | -6.25% | Barclays | $22 → $9 | Downgrades | Overweight → Equal-Weight |
| 11/08/2022 | 62.5% | Goldman Sachs | $18 → $15.6 | Maintains | Buy |
| 11/04/2022 | 87.5% | Goldman Sachs | $21 → $18 | Maintains | Buy |
| 11/04/2022 | 77.08% | Needham | $22 → $17 | Maintains | Buy |
| 11/04/2022 | 25% | RBC Capital | $15 → $12 | Downgrades | Outperform → Sector Perform |
| 09/21/2022 | 129.17% | Needham | → $22 | Initiates Coverage On | → Buy |
| 08/08/2022 | 118.75% | Goldman Sachs | $24 → $21 | Maintains | Buy |
| 03/22/2022 | 222.92% | Goldman Sachs | $35 → $31 | Maintains | Buy |
| 03/22/2022 | 118.75% | Credit Suisse | $26 → $21 | Maintains | Outperform |
| 03/16/2022 | 129.17% | Barclays | $30 → $22 | Maintains | Overweight |
| 11/23/2021 | 118.75% | Stifel | → $21 | Initiates Coverage On | → Buy |
| 11/23/2021 | 139.58% | Jefferies | → $23 | Initiates Coverage On | → Buy |
| 11/23/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 108.33% | Truist Securities | → $20 | Initiates Coverage On | → Hold |
| 11/23/2021 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 11/23/2021 | 170.83% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 11/23/2021 | 118.75% | RBC Capital | → $21 | Initiates Coverage On | → Outperform |
| 11/23/2021 | 170.83% | Baird | → $26 | Initiates Coverage On | → Outperform |
| 11/23/2021 | 212.5% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 11/23/2021 | 264.58% | Goldman Sachs | → $35 | Initiates Coverage On | → Buy |
What is the target price for HireRight Holdings (HRT)?
The latest price target for HireRight Holdings (NYSE: HRT) was reported by Truist Securities on November 8, 2023. The analyst firm set a price target for $11.00 expecting HRT to rise to within 12 months (a possible 14.58% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HireRight Holdings (HRT)?
The latest analyst rating for HireRight Holdings (NYSE: HRT) was provided by Truist Securities, and HireRight Holdings maintained their hold rating.
When is the next analyst rating going to be posted or updated for HireRight Holdings (HRT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HireRight Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HireRight Holdings was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating HireRight Holdings (HRT) correct?
While ratings are subjective and will change, the latest HireRight Holdings (HRT) rating was a maintained with a price target of $10.00 to $11.00. The current price HireRight Holdings (HRT) is trading at is $9.60, which is out of the analyst's predicted range.